Walleye Capital LLC Insmed Inc Transaction History

Walleye Capital LLC

$46.2 Billion
Q3 2024

A detailed history of Walleye Capital LLC transactions in Insmed Inc stock. As of the latest transaction made, Walleye Capital LLC holds 43,600 shares of INSM stock, worth $3.22 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

43,600

Previous 45,927 5.07%

Holding current value

$3.22 Million

Previous $3.08 Million 3.41%

% of portfolio

0.01%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$62.0 - $79.01 $1.09 Million - $1.39 Million	17,550 Added 38.21%	63,477 $4.63 Million
Q2 2024 Aug 14, 2024	SELL	$22.0 - $69.71 $3.19 Million - $10.1 Million	-145,215 Reduced 75.97%	45,927 $3.08 Million
Q1 2024 May 15, 2024	BUY	$25.72 - $29.94 $1.87 Million - $2.18 Million	72,731 Added 61.42%	191,142 $5.19 Million
Q4 2023 Feb 14, 2024	BUY	$23.42 - $31.74 $1.09 Million - $1.47 Million	46,341 Added 64.3%	118,411 $3.67 Million
Q3 2023 Nov 14, 2023	BUY	$19.86 - $26.93 $1.43 Million - $1.94 Million	72,070 New	72,070 $1.82 Million
Q1 2023 May 15, 2023	BUY	$16.26 - $21.73 $1.08 Million - $1.44 Million	66,440 New	66,440 $1.13 Million
Q3 2022 Nov 14, 2022	BUY	$20.88 - $28.21 $1.3 Million - $1.75 Million	62,177 Added 50.03%	186,462 $4.02 Million
Q2 2022 Aug 08, 2022	BUY	$17.07 - $25.71 $295,703 - $445,374	17,323 Added 16.2%	124,285 $2.45 Million
Q1 2022 May 16, 2022	BUY	$20.42 - $28.13 $1.17 Million - $1.61 Million	57,325 Added 115.49%	106,962 $2.51 Million
Q4 2021 Mar 03, 2022	BUY	$25.89 - $33.45 $1.29 Million - $1.66 Million	49,637 New	49,637 $1.35 Million

Others Institutions Holding INSM

# of Institutions

467

Shares Held

182M

Call Options Held

2.27M

Put Options Held

3.33M

View Full List

About INSMED Inc

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $10B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

More about INSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.

Account

Walleye Capital LLC Insmed Inc Transaction History